These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2962589)

  • 41. Foscarnet (phosphonoformate sodium) in the treatment of recurrent male genital herpes.
    Lim KB; Doraisingham S; Thirumoorthy T; Lee CT; Ling AE; Tan T
    Ann Acad Med Singap; 1986 Oct; 15(4):617-22. PubMed ID: 2952046
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Will new treatment cause remission in AIDS patients?
    Moran EJ
    Hospitals; 1990 Feb; 64(3):72. PubMed ID: 2298431
    [No Abstract]   [Full Text] [Related]  

  • 43. The potential of phosphonoformate for the treatment of herpex simplex labialis.
    Oxford J
    J Antimicrob Chemother; 1980 Nov; 6(6):694-5. PubMed ID: 6449499
    [No Abstract]   [Full Text] [Related]  

  • 44. Suramin therapy in AIDS and related disorders. Report of the US Suramin Working Group.
    Cheson BD; Levine AM; Mildvan D; Kaplan LD; Wolfe P; Rios A; Groopman JE; Gill P; Volberding PA; Poiesz BJ
    JAMA; 1987 Sep; 258(10):1347-51. PubMed ID: 3650339
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [AIDS treatment studies. The confusion is complete].
    Fortschr Med; 1989 Nov; 107(33):18-9. PubMed ID: 2689316
    [No Abstract]   [Full Text] [Related]  

  • 46. Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.
    Sjövall J; Bergdahl S; Movin G; Ogenstad S; Saarimäki M
    Antimicrob Agents Chemother; 1989 Jul; 33(7):1023-31. PubMed ID: 2528939
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Age-related differences in pharmacokinetics of phosphonoformate in cats.
    Swenson CL; Sams RA; Polas PJ; Michael DF; Mathes LE
    Antimicrob Agents Chemother; 1990 May; 34(5):871-4. PubMed ID: 2141779
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus.
    Sjövall J; Karlsson A; Ogenstad S; Sandström E; Saarimäki M
    Clin Pharmacol Ther; 1988 Jul; 44(1):65-73. PubMed ID: 2968875
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of sodium phosphonoformate on blood group antibody detection.
    Hunt AF; Jones MT; Howkins GJ
    Vox Sang; 1986; 51(3):231-2. PubMed ID: 2949433
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Age-related differences in phosphonoformate-induced bone toxicity in cats.
    Swenson CL; Weisbrode SE; Nagode LA; Hayes KA; Steinmeyer CL; Mathes LE
    Calcif Tissue Int; 1991 May; 48(5):353-61. PubMed ID: 1829019
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: a phase I study.
    Kahn JO; Kaplan LD; Gambertoglio JG; Bredesen D; Arri CJ; Turin L; Kibort T; Williams RL; Lifson JD; Volberding PA
    AIDS; 1990 Dec; 4(12):1197-204. PubMed ID: 2088398
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.
    Abrams DI; Kuno S; Wong R; Jeffords K; Nash M; Molaghan JB; Gorter R; Ueno R
    Ann Intern Med; 1989 Feb; 110(3):183-8. PubMed ID: 2463780
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A pilot study of diethyldithiocarbamate in patients with acquired immune deficiency syndrome (AIDS) and the AIDS-related complex.
    Brewton GW; Hersh EM; Rios A; Mansell PW; Hollinger B; Reuben JM
    Life Sci; 1989; 45(26):2509-20. PubMed ID: 2559272
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of azimexon therapy on host defense parameters and disease-associated symptoms in the acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC).
    Patt YZ; Mansell PW; Reuben JM; Claghorn L; Li S; Gehan E; Hersh EM
    AIDS Res; 1986; 2(3):191-209. PubMed ID: 3755909
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A pilot study of the bioavailability and pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS or AIDS-related complex.
    Gustavson LE; Fukuda EK; Rubio FA; Dunton AW
    J Acquir Immune Defic Syndr (1988); 1990; 3(1):28-31. PubMed ID: 2152803
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic effect of trisodium phosphonoformate on cutaneous herpesvirus infection in guinea pigs.
    Alenius S; Dinter Z; Oberg B
    Antimicrob Agents Chemother; 1978 Sep; 14(3):408-13. PubMed ID: 213015
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Open study of AL-721 treatment of HIV-infected subjects with generalized lymphadenopathy syndrome: an eight week open trial and follow-up.
    Grieco MH; Lange M; Buimovici-Klein E; Reddy MM; Englard A; McKinley GF; Ong K; Metroka C
    Antiviral Res; 1988 Apr; 9(3):177-90. PubMed ID: 2456739
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Determination of phosphonoformate (foscarnet) in biological fluids by ion-pair reversed-phase liquid chromatography.
    Pettersson KJ; Nordgren T; Westerlund D
    J Chromatogr; 1989 Mar; 488(2):447-55. PubMed ID: 2526150
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Extracorporeal photopheresis in the treatment of AIDS-related complex: a pilot study.
    Bisaccia E; Berger C; Klainer AS
    Ann Intern Med; 1990 Aug; 113(4):270-5. PubMed ID: 1973885
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ineffectiveness of AL721 in HIV disease.
    Peters BS; Bennett JM; Jeffries DJ; Knox K; Kocsis A; Pinching AJ
    Lancet; 1990 Mar; 335(8688):545-6. PubMed ID: 1968558
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.